Glucagon-like peptide-1: a basis for new approaches to the management of diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Glucagon-like peptide-1 : a basis for new approaches to the management of diabetes. / Deacon, C F; Holst, Jens Juul; Carr, R D.

In: Drugs of Today, Vol. 35, No. 3, 03.1999, p. 159-70.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Deacon, CF, Holst, JJ & Carr, RD 1999, 'Glucagon-like peptide-1: a basis for new approaches to the management of diabetes', Drugs of Today, vol. 35, no. 3, pp. 159-70.

APA

Deacon, C. F., Holst, J. J., & Carr, R. D. (1999). Glucagon-like peptide-1: a basis for new approaches to the management of diabetes. Drugs of Today, 35(3), 159-70.

Vancouver

Deacon CF, Holst JJ, Carr RD. Glucagon-like peptide-1: a basis for new approaches to the management of diabetes. Drugs of Today. 1999 Mar;35(3):159-70.

Author

Deacon, C F ; Holst, Jens Juul ; Carr, R D. / Glucagon-like peptide-1 : a basis for new approaches to the management of diabetes. In: Drugs of Today. 1999 ; Vol. 35, No. 3. pp. 159-70.

Bibtex

@article{726de16130944e17a2f253b5d64c2ce5,
title = "Glucagon-like peptide-1: a basis for new approaches to the management of diabetes",
abstract = "Type 2 diabetes mellitus is a metabolic disease resulting in raised blood sugar which, if not satisfactorily controlled, can cause severe and often debilitating complications. Unfortunately, for many patients, the existing therapies do not give adequate control. Glucagon-like peptide-1 (GLP-1) is an incretin hormone which has a spectrum of activities which oppose the symptoms of diabetes. Of particular significance is the fact that these actions are glucose-dependent, meaning that the risk of severe hypoglycemia is practically eliminated. The recent elucidation of the key role of dipeptidyl peptidase IV in determining the metabolic stability of GLP-1 has given the rationale for two novel therapeutic strategies, namely, GLP-1 analogs which are resistant to the enzyme and inhibitors of the enzyme which boost levels of endogenous intact GLP-1. These approaches aim to maximize the therapeutic advantages offered by GLP-1 and give the hope of providing effective glycemic control without the risk of overt hypoglycemia.",
author = "Deacon, {C F} and Holst, {Jens Juul} and Carr, {R D}",
note = "(c) 1999 Prous Science. All rights reserved.",
year = "1999",
month = "3",
language = "English",
volume = "35",
pages = "159--70",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "3",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1

T2 - a basis for new approaches to the management of diabetes

AU - Deacon, C F

AU - Holst, Jens Juul

AU - Carr, R D

N1 - (c) 1999 Prous Science. All rights reserved.

PY - 1999/3

Y1 - 1999/3

N2 - Type 2 diabetes mellitus is a metabolic disease resulting in raised blood sugar which, if not satisfactorily controlled, can cause severe and often debilitating complications. Unfortunately, for many patients, the existing therapies do not give adequate control. Glucagon-like peptide-1 (GLP-1) is an incretin hormone which has a spectrum of activities which oppose the symptoms of diabetes. Of particular significance is the fact that these actions are glucose-dependent, meaning that the risk of severe hypoglycemia is practically eliminated. The recent elucidation of the key role of dipeptidyl peptidase IV in determining the metabolic stability of GLP-1 has given the rationale for two novel therapeutic strategies, namely, GLP-1 analogs which are resistant to the enzyme and inhibitors of the enzyme which boost levels of endogenous intact GLP-1. These approaches aim to maximize the therapeutic advantages offered by GLP-1 and give the hope of providing effective glycemic control without the risk of overt hypoglycemia.

AB - Type 2 diabetes mellitus is a metabolic disease resulting in raised blood sugar which, if not satisfactorily controlled, can cause severe and often debilitating complications. Unfortunately, for many patients, the existing therapies do not give adequate control. Glucagon-like peptide-1 (GLP-1) is an incretin hormone which has a spectrum of activities which oppose the symptoms of diabetes. Of particular significance is the fact that these actions are glucose-dependent, meaning that the risk of severe hypoglycemia is practically eliminated. The recent elucidation of the key role of dipeptidyl peptidase IV in determining the metabolic stability of GLP-1 has given the rationale for two novel therapeutic strategies, namely, GLP-1 analogs which are resistant to the enzyme and inhibitors of the enzyme which boost levels of endogenous intact GLP-1. These approaches aim to maximize the therapeutic advantages offered by GLP-1 and give the hope of providing effective glycemic control without the risk of overt hypoglycemia.

M3 - Journal article

C2 - 12973381

VL - 35

SP - 159

EP - 170

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 3

ER -

ID: 132055919